Abstract
Abuse-deterrent opioid formulations are receiving renewed interest in light of the increasing legitimate medical use of prescription opioids for the adequate treatment of pain. Unfortunately, there is an inevitable associated potential for misuse, diversion, and abuse. The challenges of deterrence are significant: opioid abusers are a heterogeneous population; studies on drug “liking” and opioid “attractiveness” are informative, but mainly rely on reports from users who are not reliable respondents; drug “liking” scores are useful, but it is unclear how much drug “liking” must be reduced in order to achieve an actual reduction in abuse levels; and the most popular drugs among opioid abusers appear to be those that meet a complex combination of both positive and negative criteria including things like availability, pricing, and how easily the drug’s illicit use can be concealed. Several abuse-deterrent formulations have been introduced or are in development. Epidemiological studies will have to be conducted to evaluate their effectiveness. Although there are currently more questions than answers, such products are clearly of medical and societal importance.
Keywords: Opioids, opioid abuse, opioid misuse, abuse-deterrent opioids, abuse-resistant opioids, pain, availability, pricing, drug, effectiveness.
Current Pharmaceutical Design
Title:Non-Analgesic Effects of Opioids: Factors Relevant to Opioid Abuse and Abuse- Deterrent Formulations
Volume: 18 Issue: 37
Author(s): Joseph V. Pergolizzi, Robert B. Raffa, Jason S. Pergolizzi and Robert Taylor
Affiliation:
Keywords: Opioids, opioid abuse, opioid misuse, abuse-deterrent opioids, abuse-resistant opioids, pain, availability, pricing, drug, effectiveness.
Abstract: Abuse-deterrent opioid formulations are receiving renewed interest in light of the increasing legitimate medical use of prescription opioids for the adequate treatment of pain. Unfortunately, there is an inevitable associated potential for misuse, diversion, and abuse. The challenges of deterrence are significant: opioid abusers are a heterogeneous population; studies on drug “liking” and opioid “attractiveness” are informative, but mainly rely on reports from users who are not reliable respondents; drug “liking” scores are useful, but it is unclear how much drug “liking” must be reduced in order to achieve an actual reduction in abuse levels; and the most popular drugs among opioid abusers appear to be those that meet a complex combination of both positive and negative criteria including things like availability, pricing, and how easily the drug’s illicit use can be concealed. Several abuse-deterrent formulations have been introduced or are in development. Epidemiological studies will have to be conducted to evaluate their effectiveness. Although there are currently more questions than answers, such products are clearly of medical and societal importance.
Export Options
About this article
Cite this article as:
V. Pergolizzi Joseph, B. Raffa Robert, S. Pergolizzi Jason and Taylor Robert, Non-Analgesic Effects of Opioids: Factors Relevant to Opioid Abuse and Abuse- Deterrent Formulations, Current Pharmaceutical Design 2012; 18 (37) . https://dx.doi.org/10.2174/138161212803582379
DOI https://dx.doi.org/10.2174/138161212803582379 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non-Antidepressant Pharmacologic Long-Term Treatment of Panic Disorder
Current Clinical Pharmacology Advances in Extracorporeal Detoxification by MARS Dialysis in Patients with Liver Failure
Current Medicinal Chemistry Association of rs610932 and rs670139 Polymorphisms in the MS4A Gene Cluster with Alzheimer’s Disease: An Updated Meta-analysis
Current Alzheimer Research Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) An 8-Year Retrospective Study of Human Visceral Leishmaniasis
Current Clinical Pharmacology Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Current Pharmaceutical Design The Amyloid β-Protein Precursor and Alzheimers Disease. Therapeutic Approaches
Current Medicinal Chemistry - Central Nervous System Agents C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current Neuropharmacology Mass Spectrometry Techniques: Principles and Practices for Quantitative Proteomics
Current Protein & Peptide Science Assessment of Cytochrome P450 Induction in Human Hepatocytes Using the Cocktail Strategy Plus Liquid Chromatography Tandem Mass Spectrometry
Drug Metabolism Letters Application of Decoy Oligonucleotides as Novel Therapeutic Strategy: A Contemporary Overview
Current Drug Discovery Technologies Quantitative Structure Activity Relationship and Design of Phenyl Alkyl Ketone Derivatives as Inhibitors of Phosphodiesterase 4
Current Enzyme Inhibition The Forkhead Transcription Factor FOXO3a Controls Microglial Inflammatory Activation and Eventual Apoptotic Injury through Caspase 3
Current Neurovascular Research Pindolol Augmentation of Antidepressant Response
Current Drug Targets Nanoparticle Delivery Systems for DNA/RNA and their Potential Applications in Nanomedicine
Current Topics in Medicinal Chemistry Design of Molecules Acting on the Serotonin Receptors
Letters in Drug Design & Discovery Meet the Editorial Board
Mini-Reviews in Medicinal Chemistry Interactions between Antidepressants and Warfarin: A Review
Current Psychiatry Research and Reviews Microenvironmental Determinants of Adult Neural Stem Cell Proliferation and Lineage Commitment in the Healthy and Injured Central Nervous System
Current Stem Cell Research & Therapy L-Glutamate and its Ionotropic Receptors in the Nervous System of Cephalopods
Current Neuropharmacology